Merck-CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

Merck(US:MRK) Businesswire·2025-09-11 10:45

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CAPVAXIVE Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease. ...